-
Signature
-
/s/ Jonathan Golightly, attorney-in-fact
-
Stock symbol
-
RXRX
-
Transactions as of
-
Jun 29, 2023
-
Transactions value $
-
-$19,290
-
Form type
-
4
-
Date filed
-
7/3/2023, 03:21 PM
Transactions Table
Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
transaction |
RXRX |
Class A Common Stock |
Options Exercise |
$3.18K |
+3K |
+0.71% |
$1.06* |
427K |
Jun 29, 2023 |
Direct |
F1 |
transaction |
RXRX |
Class A Common Stock |
Sale |
-$22.5K |
-3K |
-0.7% |
$7.49 |
424K |
Jun 29, 2023 |
Direct |
F1, F2 |
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
transaction |
RXRX |
Stock Option (Right to Buy) |
Options Exercise |
$0 |
-3K |
-0.55% |
$0.00 |
540K |
Jun 29, 2023 |
Class A Common Stock |
3K |
$1.06 |
Direct |
F1, F4 |
holding |
RXRX |
Stock Option (Right to Buy) |
|
|
|
|
|
434K |
Jun 29, 2023 |
Class A Common Stock |
0 |
$8.55 |
Direct |
F3 |
holding |
RXRX |
Stock Option (Right to Buy) |
|
|
|
|
|
159K |
Jun 29, 2023 |
Class A Common Stock |
0 |
$11.40 |
Direct |
F5 |
holding |
RXRX |
Stock Option (Right to Buy) |
|
|
|
|
|
4.78K |
Jun 29, 2023 |
Class A Common Stock |
0 |
$11.40 |
Direct |
|
holding |
RXRX |
Stock Option (Right to Buy) |
|
|
|
|
|
150K |
Jun 29, 2023 |
Class A Common Stock |
0 |
$2.48 |
Direct |
F6 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: